New Potential Anticancer Agents Based on the Anthranilic Acid Scaffold. Synthesis and Evaluation of Biological Activity
- 15 November 2005
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 48 (26) , 8245-8252
Abstract
The synthesis and anticancer activity of new compounds designed on the anthranilic acid scaffold are reported. The antiproliferative activity was assayed by the National Cancer Institute in established in vitro and in vivo anticancer experimental models. Structural variations based on the flufenamic acid motif afforded a series of (hetero)aryl esters of N-(2-(trifluoromethyl)pyridin-4-yl)anthranilic acid, which showed in vitro growth inhibitory properties against human tumor cell lines in nanomolar to low micromolar concentrations. The pyridinyl ester 25 exhibited very potent in vitro antiproliferative efficacy, with a chemosensitive profile showing a number of GI50 values at concentrations lower than 10-7 M in the full panel of human tumor cell lines. Compound 25 was also tested in vivo as a potential anticancer agent in the hollow fiber assay and in human tumor xenografts, showing moderate inhibitory properties. Analysis of biological activities and the COMPARE procedure was utilized to support putative biochemical mechanisms implicated with the antiproliferative activity.Keywords
This publication has 22 references indexed in Scilit:
- Synthesis of new N-(2-(trifluoromethyl)pyridin-4-yl)anthranilic acid derivatives and their evaluation as anticancer agentsBioorganic & Medicinal Chemistry Letters, 2004
- Cyclooxygenase Isozymes: The Biology of Prostaglandin Synthesis and InhibitionPharmacological Reviews, 2004
- Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's MacroglobulinemiaSeminars in Oncology, 2003
- Tranilast Inhibits the Proliferation of Uterine Leiomyoma Cellsin Vitrothrough G1 Arrest Associated with the Induction of p21waf1and p53The Journal of Clinical Endocrinology & Metabolism, 2002
- Anthranilic Acid Amides: A Novel Class of Antiangiogenic VEGF Receptor Kinase InhibitorsJournal of Medicinal Chemistry, 2002
- Cyclooxygenase-2: A Therapeutic TargetAnnual Review of Medicine, 2002
- Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2Nature Reviews Cancer, 2001
- Cyclo-oxygenase 2: a pharmacological target for the prevention of cancerThe Lancet Oncology, 2001
- The Role of Cyclooxygenase Inhibition in the Antineoplastic Effects of Nonsteroidal Antiinflammatory Drugs (Nsaids)Journal of Experimental Medicine, 1999
- Annulation of functionalized hexadienones as an efficient regioselective approach to N-aryl-2-trifluoromethyl)-4-pyridinaminesTetrahedron Letters, 1999